PKU HealthCare Corp., Ltd. (000788.SZ) Latest Company News

Oct 26, 2026, 11:35 UTC
Shanghai Hongkang completed the registration of its acquisition of 100% of Synthetic Group, indirectly holding 109 million Peking University Pharmaceutical shares, or 18.29% of its total share capital; Cheng Dong became the actual controller, replacing Xu Xiren.
Source:
- finance.sina.cn
Oct 26, 2026, 10:22 UTC
Peking University Pharmaceutical reported third-quarter 2026 revenue of 205 million yuan, down 25.04% year over year, and attributable net profit of 18.1439 million yuan, down 49.16%.
Source:
- finance.sina.cn
Oct 21, 2026, 11:07 UTC
Southwest Synthetic Pharmaceutical Group is set to have up to 17.8796 million Peking University Pharmaceutical shares, or no more than 3% of its total share capital, forcibly sold following a margin-trading dispute.
Source:
- finance.sina.cn
Oct 19, 2026, 09:38 UTC
China’s National Medical Products Administration approved Peking University Pharmaceutical’s rosuvastatin and ezetimibe tablets for registration, under approval number H20266204.
Source:
- finance.sina.cn
Oct 16, 2026, 11:06 UTC
Southwest Synthetic Pharmaceutical Group was forcibly executed against and passively reduced its stake in Peking University Pharmaceutical by 5.966 million shares, or 1% of total share capital, through block trades, lowering its holding from 20% to 19%.
Source:
- finance.sina.cn
Sep 21, 2026, 10:33 UTC
Southwest Synthetic Pharmaceutical Group's stake in Peking University HealthCare was cut to 20.00% after 1.33 million shares were forcibly sold via block trade on September 17, 2026 under judicial enforcement tied to a margin-financing dispute with Zhongtai Securities.
Source:
- finance.sina.cn
Sep 2, 2026, 10:43 UTC
Southwest Synthetic Pharmaceutical Group, a shareholder holding over 5% of Peking University Pharmaceutical, had 1% of the company's shares (5.96 million shares) forcibly sold by Zhongtai Securities via centralized bidding from August 5 to September 1, 2026, due to a margin trading dispute, reducing its stake to 20.22%.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 24, 2026, 13:11 UTC
Peking University Founder Pharmaceutical Co., Ltd. proposed a cash dividend of 0.20 yuan per 10 shares (tax included) based on 596 million shares, with no bonus shares and no capital reserve conversion.
Source:
- finance.sina.cn
Aug 24, 2026, 13:11 UTC
Peking University Founder Pharmaceutical Co., Ltd. announced its first-half 2026 results: revenue of 447 million yuan, down 53.30% year-on-year; net profit attributable to shareholders of 55.6708 million yuan, down 44.49% year-on-year; non-recurring net profit of 43.3238 million yuan, down 55.87% year-on-year.
Source:
- finance.sina.cn
Jul 21, 2026, 10:14 UTC
A court in Jinan ordered the judicial enforcement of 17,879,622 shares held by Southwest Synthetic Pharmaceutical Group Co., Ltd. in Peking University Pharmaceutical Co., Ltd. due to a margin trading dispute.
Source:
- finance.sina.cn

000788.SZ

Shanghai Hongkang completed the registration of its acquisition of 100% of Synthetic Group, indirectly holding 109 million Peking University Pharmaceutical shares, or 18.29% of its total share capital; Cheng Dong became the actual controller, replacing Xu Xiren.

Peking University Pharmaceutical reported third-quarter 2026 revenue of 205 million yuan, down 25.04% year over year, and attributable net profit of 18.1439 million yuan, down 49.16%.

Southwest Synthetic Pharmaceutical Group is set to have up to 17.8796 million Peking University Pharmaceutical shares, or no more than 3% of its total share capital, forcibly sold following a margin-trading dispute.

China’s National Medical Products Administration approved Peking University Pharmaceutical’s rosuvastatin and ezetimibe tablets for registration, under approval number H20266204.

Southwest Synthetic Pharmaceutical Group was forcibly executed against and passively reduced its stake in Peking University Pharmaceutical by 5.966 million shares, or 1% of total share capital, through block trades, lowering its holding from 20% to 19%.

Southwest Synthetic Pharmaceutical Group's stake in Peking University HealthCare was cut to 20.00% after 1.33 million shares were forcibly sold via block trade on September 17, 2026 under judicial enforcement tied to a margin-financing dispute with Zhongtai Securities.

Peking University Founder Pharmaceutical Co., Ltd. proposed a cash dividend of 0.20 yuan per 10 shares (tax included) based on 596 million shares, with no bonus shares and no capital reserve conversion.

A court in Jinan ordered the judicial enforcement of 17,879,622 shares held by Southwest Synthetic Pharmaceutical Group Co., Ltd. in Peking University Pharmaceutical Co., Ltd. due to a margin trading dispute.